Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose escalation. In addition, the mechanism of act...

Descripción completa

Detalles Bibliográficos
Autores principales: Cauwels, Anje, Van Lint, Sandra, Rogge, Elke, Verhee, Annick, Van Den Eeckhout, Bram, Pang, Shengru, Prinz, Marco, Kley, Niko, Uzé, Gilles, Tavernier, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566508/
https://www.ncbi.nlm.nih.gov/pubmed/34732771
http://dx.doi.org/10.1038/s41598-021-00891-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566508/
https://www.ncbi.nlm.nih.gov/pubmed/34732771
http://dx.doi.org/10.1038/s41598-021-00891-6

Ejemplares similares